KHPG(SZ:002773)2022-12-03 10:54Group 1: Company Strategy and Market Position - The company is adapting to changes in the pharmaceutical industry due to new policies and will implement measures accordingly [4] - The promotion of the drug Conbercept (康柏西普) involves extensive training for doctors and patients to increase sales and expand into untapped markets [4] - The overseas commercialization of Conbercept is a key focus, with ongoing global multi-center clinical trials to enhance market value [5] Group 2: Clinical Trials and Product Development - The global multi-center clinical trial for Conbercept involves over 200 research centers across more than 30 countries, with plans to enroll over 2,000 participants [5] - The company is preparing for the upcoming national medical insurance negotiations, aiming to showcase the advantages of Conbercept to achieve favorable outcomes [5] - The company is actively seeking innovative projects globally that align with its strategic goals [6] Group 3: Product Pipeline and Innovations - The company is enhancing its product pipeline based on clinical needs, focusing on core therapeutic areas such as ophthalmology and neurology [6] - Conbercept has received approval for three indications: wet age-related macular degeneration (wAMD), myopic choroidal neovascularization (pmCNV), and diabetic macular edema (DME), with ongoing phase III clinical trials [7] - The company is developing KH906 eye drops for treating trauma and chemical burns, which has received clinical trial approval [7]